Zhan Myeloma

---

Study Field: Multiple Myeloma || Number of samples: 345
Number of subgroup(s): 8 [1: Proliferation PR (n=29); 2: Low bone disease LB (n=31); 3: MMSET group MS (n=42); 4: Hyperdiploïd HY (n=65); 5: CD-1 (n=22); 6: CD-2 (n=41); 7: MAF group MF (n=20); 8: Myeloïd MY (n=95)]
Chip: Affy U133P2 || Normalization: MAS5 (scaling value: 500)
--------------------------------------
Survival data: OAS, OAS_DAYS

---

Citation(s): Zhan F et al. Blood 2006 Sep 15;108(6):2020-8.

Friedman Leukemia

---

Study Field: Chronic lymphocytic leukemia (CLL) || Number of samples: 68
Number of subgroup(s): 2 [1: Patients with stable disease (n=36); 2: Patients with progressive disease (n=32)]
Chip: Affy U133P2 || Normalization: MAS5 (scaling value: 500)

---

Citation(s): Friedman et al. Clin Cancer Res 2009 Nov 15;15(22):6947-55.

Hong Colon

---

Study Field: Colorectal cancer || Number of samples: 82
Number of subgroup(s): 2 [1: Healthy control(n=12); 2: Early stage CRC patient's tumor (n=70)]
Chip: Affy U133P2 || Normalization: MAS5 (scaling value: 500)

---

Citation(s): Hong et al. Clin Exp Metastasis 2010 Feb;27(2):83-90.

Badea Pancreatic

---

Study Field: Pancreatic ductal adenocarcinoma || Number of samples: 78
Number of subgroup(s): 2 [1: Healthy control (n=39); 2: Pancreatic ductal adenocarcinoma tumors (n=39)]
Chip: Affy U133P2 || Normalization: RMA

---

Citation(s): Badea et al.  Hepatogastroenterology 2008 Nov-Dec;55(88):2016-27.

Human plasma cell differentiation MAS5

---

Study Field: Plasma cell differentiation || Number of samples: 38
Number of subgroup(s): 8 [1: Naïve B cells (n=5); 2: Centroblasts (n=4); 3: Centrocytes (n=4); 4: Memory B cells (n=5); 5: Preplasmablasts (n=5); 6: Plasmablasts (n=5); 7: Early plasma cells (n=5); 8: Bone marrow plasma cells (n=5)]
Chip: Affy U133P2 || Normalization: MAS5 (scaling value: 500)

---

Citation(s):

• Jourdan et al., J Immunol. 2011 Oct 15;187(8):3931-41. 
• Jourdan et al., Blood. 2009 Dec 10;114(25):5173-81.